NCT07486024: Feasibility of the Application of a New Six-month Treatment for Multidrug-resistant Tuberculosis (MDR-TB) Patients in France (FAST-MDR)
- State
- Under way
- Phase
- Phase 3
- People
- 55 planned
- Started
- 11 Sep 2026
- Primary completion
- Aug 2030
- Arms
- Bedaquiline - 400 mg, Bedaquiline - 200 mg
- Results
- None posted
- 20 Mar 2026: Trial registered
- 11 Sep 2026: Trial started